Blog
DOL takes aim at PBM middlemen
https://phrma.org/blog/dol-takes-aim-at-pbm-middlemen
State scrutiny of PBMs is far from over
As states search for ways to lower costs and improve access to medicines, policymakers are asking whether PBM business practices contribute to higher costs, reduced competition and barriers between patients and the medicines they need.
For example: Florida and Louisiana have filed lawsuits alleging that major PBMs engaged in practices, such as contracting arrangements, that manipulated pharmacy reimbursement and limited competition.
States are acting: They join a growing list of states, including Ohio, California, Colorado, Michigan and Illinois, that have pursued legislation, investigations or litigation, reflecting continued bipartisan concern about PBM practices.
- All 50 states have enacted laws addressing PBMs, and state action continues to grow.
- In 2026, over 30 states considered legislation, while the debate has expanded beyond simple licensure or registration of PBMs to encompass broader questions about insurer and PBM market practices.
Why the attention? The three largest PBMs control roughly 80% of the market. That gives them significant influence over:
- Which medicines patients can access
- What patients pay out of pocket
- Whether lower-cost alternatives reach patients
PBMs may prioritize profits over patients, which impacts affordability, competition and whether savings reach patients.
The challenge ahead: PBMs have repeatedly adapted their contracting arrangements, compensation structures and business models in response to increased scrutiny. That means passing reforms is not the end of the story.
What to watch: States have an opportunity to build on recent momentum and bring greater transparency and accountability to a historically opaque corner of the health care system.
The bottom line: As policymakers continue searching for affordability solutions, the question is no longer whether PBMs deserve scrutiny. Recent reforms represent meaningful progress. Now, the focus should be on ensuring those reforms work as intended and that oversight keeps pace as insurer and PBM business models evolve.
Will May
Recognizing the transformative impact of intellectual property
October marks both Intellectual Property Month and Manufacturing Month, presenting a unique opportunity to recognize the critical value of intellectual property protections and the domestic manufacturing ecosystem that they empower.
Dive deeper: Intellectual property (IP) protections are what make it possible for biopharmaceutical companies to research and develop the next generation of treatments and cures. IP is also critical to companies’ ability to build manufacturing facilities, hire skilled workforces and invest significant financial resources.
The certainty that IP protections offer America’s inventors is also what enables the manufacturing investments we are seeing nationwide. Biopharmaceutical companies are at the tip of the spear, pledging hundreds of billions of dollars in new facility investments all across the United States.
As a new TEConomy report shows, the scale of that build-out is significant:
- 350,000+ manufacturing jobs are directly supported by biopharmaceutical companies
- 1,500+ domestic manufacturing facilities across the U.S. and Puerto Rico are producing the medicines patients rely on
- $500 billion in new investments are committed to future U.S.-based biopharmaceutical manufacturing and infrastructure
That investment is already visible on the ground. New and expanded facilities are coming online to support cutting-edge cell and gene therapies, biologics and advanced small-molecule manufacturing. These sites strengthen the domestic supply chain for the medicines patients depend on. Many represent multi-billion-dollar commitments to communities across the country, creating jobs, supporting infrastructure upgrades and generating local economic growth.
There’s more: The stakes reach beyond just a single industry. According to the U.S. Patent and Trademark Office’s latest report, IP-intensive industries (which include biopharmaceuticals) accounted for $11.4 trillion in GDP in 2024 and supported nearly 66 million American jobs – proof that these protections are what keep investment, job creation and innovation moving forward across the entire economy.

The bottom line: Congress should reject policies that undermine IP protections and put future medical innovation and U.S. manufacturing investment at risk. Maintaining a strong, predictable IP system is essential to keeping America the global leader in developing—and manufacturing—the next generation of medicines.
Learn more at PhRMA.org/IP.
David Korn
Patients are paying more for their premiums and getting less
AHIP is, once again, arguing that patients receive good value for every premium dollar they spend. AHIP – the national association representing insurance companies – regularly releases the so-called premium dollar, purporting to show how much of each insurance premium dollar is spent on different health care services. Their claim is easier to make when the industry presents the data in ways that purposefully obscures where premium dollars ultimately go and how much revenue insurers retain for administrative, profit, and other overhead costs.
The problem: AHIP has created a misleading picture of their spending. They are pointing their fingers toward prescription drugs, diverting the blame of rising costs.
- AHIP’s broad “prescription drugs” category lumps together spending on brand and generic medicines with money flowing elsewhere across the pharmaceutical supply chain, including to PBMs, pharmacies and wholesalers.
- This graphic separates hospital and insurer spending into multiple categories.
- Meanwhile, it understates the full amount going toward insurer administrative costs, profits, and other expenses.

Their bottom line: Increasingly, the same companies collecting those premiums also control the prescription drug benefit.
The three largest PBMs processed nearly 80% of U.S. prescriptions in 2025 and are vertically integrated with major health insurers and pharmacies, increasing their control over the health care system. The Federal Trade Commission has found that PBMs can significantly influence which medicines are available, what patients pay and which pharmacies they can use.
Their misleading groupings of spending obscure that those dollars frequently go back to them because of how the supply chain is increasingly vertically integrated. When half of each dollar spent on innovative medicines goes to someone who doesn’t make them, it's clear that those entities are profiting off of patients.
But there’s a more fundamental issue: Patients are paying more for insurance and getting less. Delays and denials are overwhelming the system. Insurers and their PBMs control when and whether they can access their medicine. A recent study showed that 70% of brand prescriptions are initially denied by commercial insurers. It’s time for insurance to work like it’s supposed to.
The bottom line: Patients should benefit from the lower negotiated prices, rebates and other savings from manufacturers that are already flowing through the system. That means making sure those savings reach patients at the pharmacy counter and that insurers and PBMs are held accountable for how they manage prescription drug benefits.
Learn more at PhRMA.org/PBMs.
Note: BRG and AHIP data are derived from different sources and methodologies. Comparisons should be interpreted as illustrative, as complete methodological details and underlying data are not publicly available.
Caroline Dunne
Latest Blogs
ICYMI: Leaders in Richmond spotlight Virginia’s biopharma growth
Investment in American innovation continues to grow
DOL takes aim at PBM middlemen
New research shows changes to hepatitis B vaccine recommendations could increase chronic infections
State scrutiny of PBMs is far from over
ICYMI: Huntsville’s biopharma ecosystem is poised for growth
PhRMA to USTR: Use trade policy to defend American innovation
The $1.74 trillion sector powering America’s economy
How the biosimilars user fee program supports competition and patients
Explore Member-only Resources
Access exclusive advocacy, policy and research materials through the member site.
PhRMA Connect